{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-008429","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.354117+00:00","generated_at":"2026-05-26T02:10:52.116893+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"C4 Therapeutics reports FY2024 revenue $35.6M, net loss $1.52/sh; cash runway into 2027","bullets":["FY2024 revenue $35.6M (vs $20.8M in FY2023); net loss $105.3M ($1.52/sh) vs $132.5M ($2.67).","Cash $267.3M at Dec 31, 2024; expected to fund operations into 2027.","Cemsidomide dose escalation continues; next-phase trials expected to start in early 2026.","CFT1946 Phase 1/2 progressing; data in melanoma and CRC expected H2 2025.","Appointed Steve Hoerter to board; initiated CFT8919 Phase 1 in Greater China with Betta."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-008429","json":"https://secwatch.observer/filing/0001628280-25-008429.json","markdown":"https://secwatch.observer/filing/0001628280-25-008429.md","text":"https://secwatch.observer/filing/0001628280-25-008429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025008429/0001628280-25-008429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025008429/cccc-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:10:52.116893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}